IQVIA (NYSE:IQV) Sets New 52-Week High – What’s Next?

IQVIA Holdings Inc. (NYSE:IQV)’s stock price reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $228.22 and last traded at $228.1770, with a volume of 679441 shares traded. The stock had previously closed at $224.90.

Wall Street Analyst Weigh In

IQV has been the subject of a number of research reports. BMO Capital Markets initiated coverage on IQVIA in a research report on Thursday, November 13th. They issued an “outperform” rating and a $260.00 price objective for the company. Wall Street Zen cut IQVIA from a “buy” rating to a “hold” rating in a research report on Sunday, November 9th. Hsbc Global Res upgraded IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of IQVIA in a report on Wednesday, October 8th. Finally, Truist Financial restated a “buy” rating and set a $265.00 price objective (up previously from $235.00) on shares of IQVIA in a report on Wednesday, October 29th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $240.61.

IQVIA Stock Up 1.5%

The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The firm has a 50 day simple moving average of $206.64 and a two-hundred day simple moving average of $181.78. The stock has a market capitalization of $38.86 billion, a P/E ratio of 31.30, a PEG ratio of 2.52 and a beta of 1.34.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. During the same quarter in the prior year, the business earned $2.84 earnings per share. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the transaction, the insider owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. This trade represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Physician Wealth Advisors Inc. increased its stake in shares of IQVIA by 1,340.0% in the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after buying an additional 134 shares during the period. Clal Insurance Enterprises Holdings Ltd increased its position in IQVIA by 436.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 131 shares during the period. Westside Investment Management Inc. raised its holdings in IQVIA by 219.6% during the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after purchasing an additional 101 shares during the last quarter. Measured Wealth Private Client Group LLC acquired a new position in shares of IQVIA in the 3rd quarter worth approximately $30,000. Finally, Atlantic Union Bankshares Corp bought a new stake in shares of IQVIA in the 3rd quarter valued at $36,000. 89.62% of the stock is owned by institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.